IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#3051
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$0
Adi Zuloff-Shani
N/A
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CMND Clearmind Medicine Inc. | 44 | 15 | 25 | 78 | - | - | -1293.6% | -253.6% | - | - | - | - | - | 0.0x | $0 | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
Clearmind Medicine Inc. (CMND) receives a "Reduce" rating with a composite score of 43.5/100. It ranks #3051 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Outperforming peers — winners tend to keep winning over 3-12 months
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Moderate investment profile
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for CMND.
View All Ratings| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 15 | 1 | +14ALPHA |
| MOMENTUM | 78 | 83 | -5NEUTRAL |
| VALUATION | 25 | 14 | +11ALPHA |
| INVESTMENT | 45 | 85 | -40DRAG |
| STABILITY | 28 | 13 | +15ALPHA |
| SHORT INT | 89 | 99 | -10DRAG |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy -1293.6% (sector -1.9%)
GM N/A vs sector 44%, OM N/A vs sector 3%
Capital turnover N/A
Rev growth N/A, 4yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Clearmind Medicine Inc. (CMND) as a Reduce with a composite score of 43.5/100 at a current price of $1.18. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential.
Clearmind Medicine Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 43.5/100 places it at rank #3051 in our full universe.
No Moat
Medium
Poor
Fair Value
Positive momentum indicates institutional accumulation.
Stable competitive position in a defensive sector.
Below-average quality raises earnings sustainability concerns.
Vulnerability to macroeconomic shocks and interest rate volatility.
Clearmind Medicine Inc. represents a reduce based on multi-factor quantitative performance.
Clearmind Medicine Inc. receives a Reduce rating from our analysis, with a composite score of 43.5/100 and 2 out of 5 stars, ranking #3051 out of 7,333 stocks. CMND's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
Clearmind Medicine Inc. registers a weak quality score of just 15/100, indicating significant profitability challenges. The company reports a return on equity of -1293.6% (sector avg: -1.9%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
CMND registers a value score of just 25/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 1.47x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
With an investment score of 45/100, CMND exhibits moderate growth-oriented spending. Key growth metrics include a return on assets of -253.6% (sector: 0.9%). The company appears to be balancing growth investments with capital returns, though the pace of investment may not be enough to accelerate top-line growth meaningfully.
CMND shows strong momentum characteristics with a score of 78/100. The stock has been trending above key moving averages, indicating solid demand from institutional buyers. Revenue growth data is not currently available, while a beta of -1.64 reflects its sensitivity to broader market moves. This level of momentum typically signals sustained investor confidence and favorable near-term price action.
CMND's stability score of 28/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of -1.64 and a debt-to-equity ratio of 0.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
CMND's short interest factor score of 89/100 indicates very low short selling activity relative to peers — a positive signal suggesting institutional investors see limited near-term downside. Specific risk factors include micro-cap liquidity risk. As a micro-cap company with a market capitalization of $0, Clearmind Medicine Inc. benefits from the generally lower volatility and deeper liquidity associated with its size class.
Clearmind Medicine Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #3051 of 7,333 overall (58th percentile). Key comparisons include ROE of -1293.6% trailing the -1.9% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While CMND currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Quality (15) would have the largest impact on the composite score.
ROE 67986% ABOVE SECTOR MEDIAN (FAVORABLE)
Debt/Equity 100% BELOW SECTOR MEDIAN (FAVORABLE)
Above 50MA
37.18%
Net New Highs
+51081
Vancouver, Canada, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced additional positive safety topline results from the second cohort of its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the Company’s proprietary non-hallucinog
Collaboration aims to leverage Polyrizon’s advanced proprietary intranasal delivery platform to support clinical development of Clearmind’s drug candidate proprietary MEAI Raanana, Israel, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced that it has entered into a development agreement with Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind”), a cl
Key Takeaways; Cannabis Sector Curaleaf Secured Record‑Setting $500M Refinancing as Industry Shifts Organigram Posted Strong Q1 Growth as New CEO Signaled Disciplined Global Expansion Tilray Deepened UK Pharmaceutical Footprint Through New Partnership Key Takeaways; Psychedelic Sector Helus Pharma is Advancing Pipeline and Leadership as Key Clinical Readouts Approach Clearmind Strengthened Safety Case for CMND‑100 With […]
Vancouver, British Columbia--(Newsfile Corp. - February 9, 2026) - Taurus Gold Corp. (CSE: TAUR) ("Taurus" or the "Company") announces management changes at Taurus.Mr. Robert Sim resigned his position as Director and CEO of Taurus, effective February 7, 2026.Mr. Asaf Itzhaik has been appointed by the Board of Directors as a director, effective February 7, 2026.Mr. Nissim Daniel, Director of Taurus, has been appointed by the Board of Directors as the CEO, effective February 7, 2026.Asaf Itzhaik..
Vancouver, British Columbia--(Newsfile Corp. - February 19, 2026) - LDB Capital Corp. (TSXV: LDB.P) ("LDB", the "Company" or the "Resulting Issuer"), a capital pool company pursuant to Policy 2.4 of the TSX Venture Exchange (the "TSXV"), is pleased to announce that it has entered into a binding definitive share exchange agreement (the "Definitive Agreement") dated February 19, 2026 with Eventer Technologies Ltd. ("Eventer") in respect of an arm's length reverse take-over transaction which is...